🇺🇸 FDA
Patent

US 12344585

Crystalline salts of a plasma kallikrein inhibitor

granted A61KA61K9/0019A61K9/0029

Quick answer

US patent 12344585 (Crystalline salts of a plasma kallikrein inhibitor) held by BioCryst Pharmaceuticals, Inc. expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BioCryst Pharmaceuticals, Inc.
Grant date
Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K9/0019, A61K9/0029, A61K9/0053, A61P